Experience with the use of rebamipide for the correction of low-grade systemic inflammation in patients with postcovid syndrome
Journal: THE NEW ARMENIAN MEDICAL JOURNAL
Year: 2024

Patients who have undergone the acute phase of NCI are at risk of developing the so-called postcovid syndrome, which is manifested by symptoms of health impairment 12 weeks after reconsolidation, namely pain syn-